Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia
Stefania Fiorcari, Rossana Maffei, Daniela Vallerini, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
H. Yesid Estupiñán, Anna Berglöf, Rula Zain, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 184
Bruton tyrosine kinase inhibitors for multiple sclerosis
Julia Krämer, Amit Bar‐Or, Timothy J. Turner, et al.
Nature Reviews Neurology (2023) Vol. 19, Iss. 5, pp. 289-304
Open Access | Times Cited: 94
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
Marzia Palma, Tom A. Mulder, Anders Österborg
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 52
Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors
Sarah Dybowski, Sebastian Torke, Martin S. Weber
JAMA Neurology (2023) Vol. 80, Iss. 4, pp. 404-404
Closed Access | Times Cited: 16
BTK drives neutrophil activation for sterilizing antifungal immunity
Jigar V. Desai, Marissa A. Zarakas, Andrew Wishart, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 12
Open Access | Times Cited: 7
Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
Sining Zhu, Samantha Gokhale, Jaeyong Jung, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 36
Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies
Jessica S Little, Zoe Weiss, Sarah P. Hammond
Journal of Fungi (2021) Vol. 7, Iss. 12, pp. 1058-1058
Open Access | Times Cited: 36
BTK inhibitor–induced defects in human neutrophil effector activity against Aspergillus fumigatus are restored by TNF-α
Diego A. Vargas-Blanco, Olivia W. Hepworth, Kyle J. Basham, et al.
JCI Insight (2024) Vol. 9, Iss. 12
Open Access | Times Cited: 5
Ibrutinib enhances the bias of T cell responses towards staphylococcal superantigens sustaining inflammation in chronic lymphocytic leukaemia
Fisal Tantoush, David Allsup, Leigh Naylor‐Adamson, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Nurse-Like Cells and Chronic Lymphocytic Leukemia B Cells: A Mutualistic Crosstalk inside Tissue Microenvironments
Stefania Fiorcari, Rossana Maffei, Claudio Giacinto Atene, et al.
Cells (2021) Vol. 10, Iss. 2, pp. 217-217
Open Access | Times Cited: 28
Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
Sining Zhu, Jaeyong Jung, Eton Victor, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 23
BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review
Michael Stack, Keith Sacco, Riccardo Castagnoli, et al.
Clinical Immunology (2021) Vol. 230, pp. 108816-108816
Open Access | Times Cited: 22
Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies
Daniel Rivera, Alessandra Ferrajoli
Current Oncology Reports (2022) Vol. 24, Iss. 8, pp. 1003-1014
Open Access | Times Cited: 14
Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents
Andrea Galitzia, Monica Maccaferri, Francesca Romana Mauro, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 1996-1996
Open Access | Times Cited: 2
Clinical Mycology Today: Emerging Challenges and Opportunities
Jessica S Little, Adriana M. Rauseo, Julio C Zuniga-Moya, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 7
Open Access | Times Cited: 2
Evaluation of infectious morbidity due to BTK inhibitors in indolent B-cell lymphomas: latest research findings and systematic analysis
Constantin A Dasanu, S.K. Mann, Melvin Baidya, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 11, pp. 1525-1540
Closed Access | Times Cited: 2
Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
Omar Alkharabsheh, Alhareth Alsayed, Diana Morlote, et al.
Current Oncology (2021) Vol. 28, Iss. 1, pp. 837-841
Open Access | Times Cited: 16
BTK Inhibitors Impair Platelet-Mediated Antifungal Activity
Vincenzo Nasillo, Ivana Lagreca, Daniela Vallerini, et al.
Cells (2022) Vol. 11, Iss. 6, pp. 1003-1003
Open Access | Times Cited: 12
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect
Haoran Wang, Hao Guo, Jingyi Yang, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 12
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients
Shirley D’Sa, J V Matous, Ranjana H. Advani, et al.
Seminars in Hematology (2023) Vol. 60, Iss. 2, pp. 80-89
Open Access | Times Cited: 6
SOHO State of the Art Updates and Next Questions | Infections in Chronic Lymphocytic Leukemia Patients: Risks and Management
Ernesto Gargiulo, Eduardo Flávio Oliveira Ribeiro, Carsten Utoft Niemann
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 5, pp. 322-332
Closed Access | Times Cited: 5
Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors
Francesca Romana Mauro, Anna Maria Frustaci, Andrea Visentin, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 201, pp. 104408-104408
Closed Access | Times Cited: 1
Bruton's tyrosine kinase inhibition suppresses pathological retinal angiogenesis
Siyue Chen, Yuming Liu, Yutian Zhang, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 1
Fungal infection in patients treated with Bruton's Tyrosine Kinase inhibitor, from epidemiology to clinical outcome: A systematic review
Charles Gibert, Marion Blaize, Arnaud Fekkar
Clinical Microbiology and Infection (2024)
Closed Access | Times Cited: 1
Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
Leigh Naylor‐Adamson, Anisha R. Chacko, Zoe Booth, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top